{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:35:05Z","timestamp":1789608905495,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijtb.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:51:53Z","timestamp":1758379913000},"page":"284-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice?"],"prefix":"10.1016","volume":"73","author":[{"given":"Amit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulomi","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-2753","authenticated-orcid":false,"given":"Shashank","family":"Shastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijtb.2025.09.005_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-007490","article-title":"Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study","volume":"7","author":"Perrin","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"12","key":"10.1016\/j.ijtb.2025.09.005_bib2","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1016\/S2666-5247(23)00321-X","article-title":"Emerging bedaquiline-resistant tuberculosis","volume":"4","author":"Lange","year":"2023","journal-title":"Lancet Microbe"},{"issue":"20","key":"10.1016\/j.ijtb.2025.09.005_bib3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and Delamanid in therapy for tuberculosis","volume":"373","author":"Bloemberg","year":"2015","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.ijtb.2025.09.005_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijtb.2020.09.003","article-title":"Pretomanid: the latest USFDA-approved anti-tuberculosis drug","volume":"68","author":"Deb","year":"2021","journal-title":"Indian J Tubercul"},{"key":"10.1016\/j.ijtb.2025.09.005_bib5","first-page":"186","article-title":"Mechanisms of resistance to Delamanid, a drug for mycobacterium tuberculosis. Tuberculosis (Edinb). 2018 Jan","volume":"108","author":"Fujiwara","year":"2018","journal-title":"Erratum in: Tuberculosis (Edinb)"},{"issue":"1","key":"10.1016\/j.ijtb.2025.09.005_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01948-20","article-title":"Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and Delamanid in Mycobacterium tuberculosis","volume":"65","author":"Rifat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ijtb.2025.09.005_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008287","article-title":"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijtb.2025.09.005_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01755-19","article-title":"Adduct formation of delamanid with NAD in mycobacteria","volume":"64","author":"Hayashi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10096-019-03551-w","article-title":"Comparison of in vitro activity of the nitroimidazoles Delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis","volume":"38","author":"Wen","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijtb.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of Delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"Von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijtb.2025.09.005_bib12","article-title":"A narrative review of bedaquiline and Delamanid: new arsenals against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis","volume":"38","author":"Ahmad Khosravi","year":"2024","journal-title":"J Clin Lab Anal"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725002161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725002161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:04:59Z","timestamp":1776877499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570725002161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0019570725002161"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.09.005","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice?","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}